Lupin has received US health regulator’s approval for generic Tamiflu Capsules.
The company stated that, it has received final approval for its Oseltamivir Phosphate Capsules USP, 30 mg, 45 mg, and 75 mg from the United States Food and Drug Administration (USFDA) to market generic version of Hoffman-La Roche, Inc’s Tamiflu Capsules 30 mg, 45 mg, and 75 mg.
Further, the drug which has received approval is suggested for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older, who has symptoms for not more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older.